Gilead Sciences Inc (GILD) 91.32 $GILD
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - 2 hrs 51 mins ago
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)
AHF: Gilead Says it "Had No Duty to Develop ..." Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit
Business Wire - Fri Mar 25, 4:42PM CDT
--According to the legal news website, Law360, Gilead attorneys, in a motion to dismiss AHF's lawsuit, wrote, "Just as Gilead was under no antitrust duty to bring a standalone TAF product to market, it likewise had no duty to develop, test, seek approval of or launch its new product on any particular timetable."
GILD: 91.32 (+1.24)
Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 25, 4:21PM CDT
SOURCE: FLICKR USER BILL BROOKS. A jury in Northern California has weighed in and decided that Gilead Sciences ' mega-blockbuster drugs Sovaldi and Harvoni violate two patents co-owned by Merck & Co and Ionis Pharmaceuticals . However,...
GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), IONS: 41.62 (+1.82)
Jury: Gilead owes Merck $200M in damages over drug patents
By LINDA A. JOHNSON - AP - Fri Mar 25, 12:43PM CDT
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.
GILD: 91.32 (+1.24), MRK: 53.07 (-0.01)
Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
at The Street - Fri Mar 25, 9:30AM CDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
BIIB: 254.69 (-0.55), GILD: 91.32 (+1.24), EDIT: 31.31 (+0.86), MRK: 53.07 (-0.01), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)
Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
Arpita Dutt - Zacks Investment Research - Thu Mar 24, 2:15PM CDT
It was all about patent infringement lawsuits this week in the biotech sector with a couple of high profile jury rulings taking center-stage.
BIIB: 254.69 (-0.55), BMRN: 80.87 (+0.26), KITE: 42.37 (-0.07), GILD: 91.32 (+1.24), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 103.61 (+2.07), HST: 16.18 (unch), MDLZ: 39.51 (-0.43), HON: 111.32 (-0.89), CAH: 81.48 (+0.20), KORS: 55.53 (-0.40), IDA: 74.11 (+0.08), DO: 21.96 (+0.06), AMAT: 20.15 (-0.13), EOG: 74.30 (-0.04), MSFT: 54.21 (+0.24), REV: 35.99 (+0.50), MU: 10.50 (-0.15), HAR: 85.66 (+0.57), SWKS: 76.20 (-0.10), PFE: 30.08 (-0.11), MCHP: 48.12 (+0.16), LLTC: 44.26 (+0.14), UL: 44.63 (+0.03), MGM: 20.52 (-0.24), CELG: 100.54 (+0.62), GILD: 91.32 (+1.24), TXN: 56.70 (+0.10), MRK: 53.07 (-0.01), QLGC: 13.01 (+0.12), ADI: 58.64 (+0.31), MRO: 10.29 (+0.10), CVX: 94.85 (+1.26), XRAY: 59.62 (-0.93), NVS: 73.30 (-0.61), GRMN: 38.97 (-0.36), CCE: 49.59 (-0.21), K: 75.44 (+0.40), JNPR: 25.36 (-0.28), IBM: 147.95 (+2.55), APA: 48.85 (+0.99), GOOGL: 754.84 (-2.72), TER: 21.09 (+0.03), ALGN: 70.23 (+0.45), MET: 42.30 (-1.11), DISCA: 27.99 (+0.18), FCAU: 7.62 (-0.15), ISIL: 13.21 (+0.18), ORCL: 40.97 (+0.22), SQ: 12.88 (+0.29), GS: 153.00 (-1.08), QRVO: 49.24 (-0.28), LRCX: 78.88 (-0.48), BAX: 40.11 (-0.58), GM: 30.96 (-0.35), CRUS: 34.47 (-0.11), PG: 82.89 (+0.07), AVGO: 153.00 (+0.01), GSBD: 19.89 (unch), CRM: 72.44 (+0.66)
Stock Market News for March 24, 2016
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:10AM CDT
Benchmarks closed in the red on Wednesday following losses in energy and materials stocks due to decline in crude prices
NKE: 61.65 (-0.79), FCX: 10.11 (+0.36), NEM: 25.40 (+0.42), COP: 40.04 (+0.19), XOM: 83.98 (+0.23), AA: 9.57 (+0.25), PXD: 139.19 (+2.42), LYB: 85.37 (+0.66), GILD: 91.32 (+1.24), IBM: 147.95 (+2.55), CHK: 4.25 (+0.12), MRK: 53.07 (-0.01), EOG: 74.30 (-0.04), DD: 63.95 (+0.20), OXY: 68.51 (+0.22), CVX: 94.85 (+1.26)
AbbVie Inc.'s Big Win Over Gilead Sciences Wasn't in Hepatitis C
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:16AM CDT
SOURCE: ABBVIE INC. Following the launch of Viekira Pak in January 2015, industry watchers speculated that AbbVie may win away significant market share from Gilead Sciences ' hepatitis C drug Harvoni. That hasn't happened, but what has...
GILD: 91.32 (+1.24), ABBV: 56.12 (-0.24)
Nike and Newmont Mining fall; Pepco, Health Net rise
AP - Wed Mar 23, 3:55PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq stock market:
POM: 26.93 (+5.69), GILD: 91.32 (+1.24), NKE: 61.65 (-0.79), CERU: 2.72 (-0.10), FRED: 14.42 (+0.34), RHT: 73.24 (+0.70), NEM: 25.40 (+0.42), HNT: 67.19 (+2.38)
Another Slide in Crude Oil Beats Up Stocks
at The Street - Wed Mar 23, 3:06PM CDT
Another swing lower for crude oil couples with continuing developments in Brussels on Wednesday to keep investors weary.
KMI: 18.09 (+0.34), NKE: 61.65 (-0.79), GMCR: 91.67 (-0.28), COP: 40.04 (+0.19), LYB: 85.37 (+0.66), RDS.A: 48.28 (+0.58), VA: 34.17 (-0.55), GILD: 91.32 (+1.24), BHP: 25.64 (+0.12), MRK: 53.07 (-0.01), PF: 44.48 (+0.91), RIO: 27.71 (+0.04), CVX: 94.85 (+1.26), YUM: 79.35 (-1.20), XLE: 61.84 (+0.30)
Cramer: After Belgium, Ask Yourself, Who Has Pricing Power and Who Doesn't?
at The Street - Wed Mar 23, 2:50PM CDT
The ability to raise prices without resistance tells you which stocks will bounce back fastest after yesterday.
GILD: 91.32 (+1.24), FB: 113.05 (+0.51), MCD: 123.29 (-0.90), GOOGL: 754.84 (-2.72), AAPL: 105.67 (-0.46)
Stocks Trade Lower as Crude Settles Below $40
at The Street - Wed Mar 23, 1:41PM CDT
Stocks post modest losses on Wednesday after crude oil settles below $40 a barrel.
VA: 34.17 (-0.55), NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), GMCR: 91.67 (-0.28), MRK: 53.07 (-0.01), RHT: 73.24 (+0.70), PF: 44.48 (+0.91), KKD: 14.61 (+0.32), GIS: 61.36 (+0.35), YUM: 79.35 (-1.20)
Nasdaq Lags In Down Session; Virgin America Soars On Deal Chatter
at Investor's Business Daily - Wed Mar 23, 12:20PM CDT
The stock market saw red in afternoon trading Wednesday, still shaken a bit by Tuesday's terror attacks in Belgium. After two days of gains, biotechs weighed on the Nasdaq, which fell 0.7%. Selling was less intense in the NYSE indexes as the S&P 500...
IPHI: 33.51 (+0.57), VA: 34.17 (-0.55), GILD: 91.32 (+1.24), ORLY: 274.76 (-1.68), MRK: 53.07 (-0.01), GLD: 116.33 (-0.28), FIVE: 40.38 (-1.16)
The Surprising Winner in Merck's Patent War With Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 23, 11:01AM CDT
Image source: Gilead Sciences. Merck & Co. 's recently launched Zepatier is challenging Gilead Sciences ' dominance in the hepatitis C marketplace, but an equally important challenge by Merck is occurring in California courts. This week,...
GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), IONS: 41.62 (+1.82)
Stocks Maintain Lows as Crude Inventories Surge
at The Street - Wed Mar 23, 9:48AM CDT
Stocks hold at session lows on Wednesday morning after crude oil inventories increase more than expected in the past week.
NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), GMCR: 91.67 (-0.28), MRK: 53.07 (-0.01), RHT: 73.24 (+0.70), PF: 44.48 (+0.91), KKD: 14.61 (+0.32), GIS: 61.36 (+0.35)
Stocks Edge Lower At Open; Merck Rises On Patent Ruling
at Investor's Business Daily - Wed Mar 23, 8:44AM CDT
Stocks opened marginally lower Wednesday on the heels of Tuesday's resilient performance in light of the terror attacks in Belgium. The Nasdaq, S&P 500 and Dow Jones industrial average all fell around 0.3%. Overseas action was quiet, with China's...
CALM: 50.12 (-0.38), NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), AMAT: 20.15 (-0.13), MRK: 53.07 (-0.01), WYNN: 93.47 (+1.71)
Gilead Sciences' Cancer Folly
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 23, 8:42AM CDT
SOURCE: GILEAD SCIENCES. Gilead Sciences reported last week that it has halted six trials that were evaluating the use of its oncology drug, Zydelig, in newly diagnosed cancer patients. The news came alongside an FDA warning to doctors of...
JNJ: 108.31 (-0.19), GILD: 91.32 (+1.24), ABBV: 56.12 (-0.24)
Gilead (GILD) Stock Down as Merck Wins Patents Dispute
at The Street - Wed Mar 23, 8:16AM CDT
Gilead (GILD) stock is lower in pre-market trading on Wednesday after a jury upheld the validity of two Merck patents, allowing Merck to seek royalties from the company.
GILD: 91.32 (+1.24)
Stock Futures Flat as Markets Move on From Brussels Attack
at The Street - Wed Mar 23, 7:39AM CDT
Stock futures are largely flat on Wednesday morning as investors overcome jitters tied to a terrorist attack in Brussels a day earlier.
NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), GMCR: 91.67 (-0.28), MRK: 53.07 (-0.01), RHT: 73.24 (+0.70), PF: 44.48 (+0.91), KKD: 14.61 (+0.32), GIS: 61.36 (+0.35)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - 2 hrs 51 mins ago
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)
AHF: Gilead Says it "Had No Duty to Develop ..." Less Harmful AIDS Drug in Legal Motion on Patent Lawsuit
Business Wire - Fri Mar 25, 4:42PM CDT
--According to the legal news website, Law360, Gilead attorneys, in a motion to dismiss AHF's lawsuit, wrote, "Just as Gilead was under no antitrust duty to bring a standalone TAF product to market, it likewise had no duty to develop, test, seek approval of or launch its new product on any particular timetable."
GILD: 91.32 (+1.24)
Patent Payoff? Merck's and Ionis Pharmaceuticals' Take Could Be Tiny
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 25, 4:21PM CDT
SOURCE: FLICKR USER BILL BROOKS. A jury in Northern California has weighed in and decided that Gilead Sciences ' mega-blockbuster drugs Sovaldi and Harvoni violate two patents co-owned by Merck & Co and Ionis Pharmaceuticals . However,...
GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), IONS: 41.62 (+1.82)
Jury: Gilead owes Merck $200M in damages over drug patents
By LINDA A. JOHNSON - AP - Fri Mar 25, 12:43PM CDT
The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.
GILD: 91.32 (+1.24), MRK: 53.07 (-0.01)
Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital
at The Street - Fri Mar 25, 9:30AM CDT
A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.
BIIB: 254.69 (-0.55), GILD: 91.32 (+1.24), EDIT: 31.31 (+0.86), MRK: 53.07 (-0.01), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)
Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
Arpita Dutt - Zacks Investment Research - Thu Mar 24, 2:15PM CDT
It was all about patent infringement lawsuits this week in the biotech sector with a couple of high profile jury rulings taking center-stage.
BIIB: 254.69 (-0.55), BMRN: 80.87 (+0.26), KITE: 42.37 (-0.07), GILD: 91.32 (+1.24), AMGN: 149.24 (+0.48), IONS: 41.62 (+1.82), REGN: 370.80 (+5.42)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 103.61 (+2.07), HST: 16.18 (unch), MDLZ: 39.51 (-0.43), HON: 111.32 (-0.89), CAH: 81.48 (+0.20), KORS: 55.53 (-0.40), IDA: 74.11 (+0.08), DO: 21.96 (+0.06), AMAT: 20.15 (-0.13), EOG: 74.30 (-0.04), MSFT: 54.21 (+0.24), REV: 35.99 (+0.50), MU: 10.50 (-0.15), HAR: 85.66 (+0.57), SWKS: 76.20 (-0.10), PFE: 30.08 (-0.11), MCHP: 48.12 (+0.16), LLTC: 44.26 (+0.14), UL: 44.63 (+0.03), MGM: 20.52 (-0.24), CELG: 100.54 (+0.62), GILD: 91.32 (+1.24), TXN: 56.70 (+0.10), MRK: 53.07 (-0.01), QLGC: 13.01 (+0.12), ADI: 58.64 (+0.31), MRO: 10.29 (+0.10), CVX: 94.85 (+1.26), XRAY: 59.62 (-0.93), NVS: 73.30 (-0.61), GRMN: 38.97 (-0.36), CCE: 49.59 (-0.21), K: 75.44 (+0.40), JNPR: 25.36 (-0.28), IBM: 147.95 (+2.55), APA: 48.85 (+0.99), GOOGL: 754.84 (-2.72), TER: 21.09 (+0.03), ALGN: 70.23 (+0.45), MET: 42.30 (-1.11), DISCA: 27.99 (+0.18), FCAU: 7.62 (-0.15), ISIL: 13.21 (+0.18), ORCL: 40.97 (+0.22), SQ: 12.88 (+0.29), GS: 153.00 (-1.08), QRVO: 49.24 (-0.28), LRCX: 78.88 (-0.48), BAX: 40.11 (-0.58), GM: 30.96 (-0.35), CRUS: 34.47 (-0.11), PG: 82.89 (+0.07), AVGO: 153.00 (+0.01), GSBD: 19.89 (unch), CRM: 72.44 (+0.66)
Stock Market News for March 24, 2016
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 9:10AM CDT
Benchmarks closed in the red on Wednesday following losses in energy and materials stocks due to decline in crude prices
NKE: 61.65 (-0.79), FCX: 10.11 (+0.36), NEM: 25.40 (+0.42), COP: 40.04 (+0.19), XOM: 83.98 (+0.23), AA: 9.57 (+0.25), PXD: 139.19 (+2.42), LYB: 85.37 (+0.66), GILD: 91.32 (+1.24), IBM: 147.95 (+2.55), CHK: 4.25 (+0.12), MRK: 53.07 (-0.01), EOG: 74.30 (-0.04), DD: 63.95 (+0.20), OXY: 68.51 (+0.22), CVX: 94.85 (+1.26)
AbbVie Inc.'s Big Win Over Gilead Sciences Wasn't in Hepatitis C
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:16AM CDT
SOURCE: ABBVIE INC. Following the launch of Viekira Pak in January 2015, industry watchers speculated that AbbVie may win away significant market share from Gilead Sciences ' hepatitis C drug Harvoni. That hasn't happened, but what has...
GILD: 91.32 (+1.24), ABBV: 56.12 (-0.24)
Nike and Newmont Mining fall; Pepco, Health Net rise
AP - Wed Mar 23, 3:55PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq stock market:
POM: 26.93 (+5.69), GILD: 91.32 (+1.24), NKE: 61.65 (-0.79), CERU: 2.72 (-0.10), FRED: 14.42 (+0.34), RHT: 73.24 (+0.70), NEM: 25.40 (+0.42), HNT: 67.19 (+2.38)
Another Slide in Crude Oil Beats Up Stocks
at The Street - Wed Mar 23, 3:06PM CDT
Another swing lower for crude oil couples with continuing developments in Brussels on Wednesday to keep investors weary.
KMI: 18.09 (+0.34), NKE: 61.65 (-0.79), GMCR: 91.67 (-0.28), COP: 40.04 (+0.19), LYB: 85.37 (+0.66), RDS.A: 48.28 (+0.58), VA: 34.17 (-0.55), GILD: 91.32 (+1.24), BHP: 25.64 (+0.12), MRK: 53.07 (-0.01), PF: 44.48 (+0.91), RIO: 27.71 (+0.04), CVX: 94.85 (+1.26), YUM: 79.35 (-1.20), XLE: 61.84 (+0.30)
Cramer: After Belgium, Ask Yourself, Who Has Pricing Power and Who Doesn't?
at The Street - Wed Mar 23, 2:50PM CDT
The ability to raise prices without resistance tells you which stocks will bounce back fastest after yesterday.
GILD: 91.32 (+1.24), FB: 113.05 (+0.51), MCD: 123.29 (-0.90), GOOGL: 754.84 (-2.72), AAPL: 105.67 (-0.46)
Stocks Trade Lower as Crude Settles Below $40
at The Street - Wed Mar 23, 1:41PM CDT
Stocks post modest losses on Wednesday after crude oil settles below $40 a barrel.
VA: 34.17 (-0.55), NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), GMCR: 91.67 (-0.28), MRK: 53.07 (-0.01), RHT: 73.24 (+0.70), PF: 44.48 (+0.91), KKD: 14.61 (+0.32), GIS: 61.36 (+0.35), YUM: 79.35 (-1.20)
Nasdaq Lags In Down Session; Virgin America Soars On Deal Chatter
at Investor's Business Daily - Wed Mar 23, 12:20PM CDT
The stock market saw red in afternoon trading Wednesday, still shaken a bit by Tuesday's terror attacks in Belgium. After two days of gains, biotechs weighed on the Nasdaq, which fell 0.7%. Selling was less intense in the NYSE indexes as the S&P 500...
IPHI: 33.51 (+0.57), VA: 34.17 (-0.55), GILD: 91.32 (+1.24), ORLY: 274.76 (-1.68), MRK: 53.07 (-0.01), GLD: 116.33 (-0.28), FIVE: 40.38 (-1.16)
The Surprising Winner in Merck's Patent War With Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 23, 11:01AM CDT
Image source: Gilead Sciences. Merck & Co. 's recently launched Zepatier is challenging Gilead Sciences ' dominance in the hepatitis C marketplace, but an equally important challenge by Merck is occurring in California courts. This week,...
GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), IONS: 41.62 (+1.82)
Stocks Maintain Lows as Crude Inventories Surge
at The Street - Wed Mar 23, 9:48AM CDT
Stocks hold at session lows on Wednesday morning after crude oil inventories increase more than expected in the past week.
NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), GMCR: 91.67 (-0.28), MRK: 53.07 (-0.01), RHT: 73.24 (+0.70), PF: 44.48 (+0.91), KKD: 14.61 (+0.32), GIS: 61.36 (+0.35)
Stocks Edge Lower At Open; Merck Rises On Patent Ruling
at Investor's Business Daily - Wed Mar 23, 8:44AM CDT
Stocks opened marginally lower Wednesday on the heels of Tuesday's resilient performance in light of the terror attacks in Belgium. The Nasdaq, S&P 500 and Dow Jones industrial average all fell around 0.3%. Overseas action was quiet, with China's...
CALM: 50.12 (-0.38), NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), AMAT: 20.15 (-0.13), MRK: 53.07 (-0.01), WYNN: 93.47 (+1.71)
Gilead Sciences' Cancer Folly
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 23, 8:42AM CDT
SOURCE: GILEAD SCIENCES. Gilead Sciences reported last week that it has halted six trials that were evaluating the use of its oncology drug, Zydelig, in newly diagnosed cancer patients. The news came alongside an FDA warning to doctors of...
JNJ: 108.31 (-0.19), GILD: 91.32 (+1.24), ABBV: 56.12 (-0.24)
Gilead (GILD) Stock Down as Merck Wins Patents Dispute
at The Street - Wed Mar 23, 8:16AM CDT
Gilead (GILD) stock is lower in pre-market trading on Wednesday after a jury upheld the validity of two Merck patents, allowing Merck to seek royalties from the company.
GILD: 91.32 (+1.24)
Stock Futures Flat as Markets Move on From Brussels Attack
at The Street - Wed Mar 23, 7:39AM CDT
Stock futures are largely flat on Wednesday morning as investors overcome jitters tied to a terrorist attack in Brussels a day earlier.
NKE: 61.65 (-0.79), GILD: 91.32 (+1.24), GMCR: 91.67 (-0.28), MRK: 53.07 (-0.01), RHT: 73.24 (+0.70), PF: 44.48 (+0.91), KKD: 14.61 (+0.32), GIS: 61.36 (+0.35)
